Core Viewpoint - Novo Nordisk's semaglutide (brand name: "Wegovy") has demonstrated significant cardiovascular benefits in overweight or obese patients with cardiovascular diseases, reducing the risk of heart attacks, strokes, and cardiovascular-related deaths by 57% compared to Eli Lilly's GLP-1 drug tirzepatide [3][4]. Group 1: Novo Nordisk's Research Findings - The STEER study, involving over 20,000 patients, showed that semaglutide 2.4mg has superior cardiovascular benefits in real-world settings compared to previous clinical trials, which indicated a 20% reduction in cardiovascular events [3]. - Semaglutide is currently the only GLP-1 drug proven to provide cardiovascular benefits in obese patients without diabetes [3]. Group 2: Eli Lilly's Developments - Eli Lilly's orforglipron, an oral GLP-1 drug, has shown clinical benefits in key cardiovascular risk factors such as non-HDL cholesterol, systolic blood pressure, and triglycerides, with a global regulatory submission for obesity treatment expected this year [4]. Group 3: Industry Trends and Other Companies - The ESC annual meeting highlighted ongoing industry focus on weight loss, blood pressure reduction, and lipid lowering, with significant research results from companies like AstraZeneca and Merck [5]. - AstraZeneca's Baxdrostat trial data offers a new treatment option for resistant hypertension, while Merck presented real-world evidence and clinical trial data on various severe cardiovascular diseases [5]. - LDL-C remains the primary target for lipid treatment, with new drug developments focusing on small nucleic acid drugs targeting Lp(a) and advancements in triglyceride-targeting therapies [5].

Core Viewpoint - The National Medical Products Administration (NMPA) of China has approved an update to the label of Novo Nordisk's semaglutide (2.4mg), indicating cardiovascular benefits based on the SELECT trial results [1] Group 1: Product Update - The updated label for Novo Nordisk's semaglutide includes findings that it can reduce the risk of major adverse cardiovascular events (MACE) by 20% in overweight or obese adults with established cardiovascular disease but without diabetes [1]